BioHealth Innovation, Inc. (BHI) provides international companies the perfect starting point to create or locate US-based subsidiaries by offering a soft landing to companies seeking to grow their US business and access BHI, federal and state resources. For more information, click here.
To foster development, production and marketing of the next generation of medical devices designed to meet growing children’s unique needs, the Food and Drug Administration (FDA) awarded $5 million to the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), led by Children’s National Health System and University of Maryland, College Park. New Consortium members include BioHealth Innovation, Inc., a Maryland-based innovation intermediary that supports the transformation of research projects into new business opportunities, and MedTech Innovator, a California-based virtual startup accelerator that matches health care industry leaders with early-stage and emerging growth medtech companies for mentorship and support. NCC-PDI’s affiliated members include industry leaders such as Smithwise, Epidarex, and Cadence.
Consulting Assistance
BHI’s team of EIRs, analysts, and SBIR consultants can help you improve your SBIR and other non-dilutive funding applications for biohealth related projects. Services include review and editing to increase the competitiveness of the grant applications, as well as more in-depth grant writing support. Depending upon the type of award sought, company resources, status of the technology, etc., the company’s obligation may be nothing until an award is granted or a nominal fee up front and the remainder only after the award has been granted.
For more information contact Jon Nelson at jnelson@biohealthinnovation.org.
MedImmune Sr. Director, Partnering & Strategy filling role previously held by Emergent BioSolutions CEO, Daniel J. Abdun-Nabi
BioHealth Innovation, Inc. (BHI) announced that its Board of Directors has unanimously approved the appointment of MedImmune Sr. Director, Partnering & Strategy, Jarrod Borkat as new Vice Chairman. MedImmune, the global biologics research and development arm of AstraZeneca, is a Founding Partner of BHI and continues to be a leader in building the BioHealth Capital Region. BHI would like to thank Emergent BioSolutions CEO, Daniel J. Abdun-Nabi, for his service as Vice Chairman. He will remain as a member of the Board of Directors. Mr. Abdun-Nabi also previously served as chairman of the Maryland Life Sciences Advisory Board (LSAB) and currently serves on Maryland Governor Larry Hogan’s Excel Board.
Company’s announcement latest in recent trend of significant investment in Montgomery County biohealth companies.
BeneVir Biopharm, Inc. (BeneVir), a privately-held Montgomery County biotech company, has entered into an agreement under which it will be acquired by Janssen Biotech, Inc., a Johnson & Johnson company for up to $1.04 billion. Under the terms of the agreement, Janssen will make an upfront cash payment of $140 million at closing of the transaction, plus additional contingent payments of up to $900 million based on achievement of certain predetermined milestones. BeneVir was a client of BioHealth Innovation (BHI) from 2013 until its Series A investment in 2014.
Welcome to the 2018 BioHealth Capital Region Forum: State of the BioHealth Capital Region’s EcoSystem
Presented by: Rich Bendis, President & CEO, BioHealth Innovation Inc.
